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MDA     malondialdehydes 
Meth     methanol  
mg GAE/1g   mg gallic acid equivalents per 1g of plant material 
mM FE /1 mg    mM Ferrous equivalents per 1mg of the dry extract 
mg QE/1g   mg quercetin equivalents per 1g of plant material 
NaCl    sodium chloride 
NCD    non-communicable disease 
NHMS    National Health and Morbidity Surveys 




−    superoxide anion radical   
OD    optical density 
OH    hydroxyl radical 
QE     quercetin equivalent  
RAAS    renin –angiotensin –aldosterone system  
RE     rutin equivalent   
Rf values    retention factor  
ROS    reactive oxygen species 
R2    regression coefficient 
S. polyanthum   Syzygium polyanthum 
SBP    systolic blood pressure 
S.D.    standard deviation 
SEM    scanning electron microscope 
S.E.M.    standard error of the means 
SGPT/ ALT serum glutamic pyruvic transaminase/ Alanine 
transaminase 
SHR    spontaneously hypertensive rats 
SOD    superoxide dismutase  
T&CM   traditional and complementary medicine 
TAC    total antioxidant capacity 
TBA    thiobarbituric acid  
TFC    total flavonoid content 
TLC    thin-layer chromatography  
TPC    total phenolic content 
TPTZ    2,4,6-Tris (2-pyridyl)-s-triazine 
UAE    ultrasound-assisted extraction  
UV    ultraviolet 
UV-Vis    ultraviolet-visible  
V     volume of the extract 
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VSMC    vascular smooth muscle cell 
WHO    World Health Organization 
WKY    wistar Kyoto  
X    distance of solvent front travelled from its origin 
XO    xanthine oxidase 
Y    distance of spot travelled from its origin 
α     type 1 error probability 
β     power of study 
δ     the difference in means for selected parameter 
σ     within group standard deviation  
m     ratio of control to experimental group 






















PENILAIAN EKSTRAK AKUEUS DAUN Syzygium polyanthum SEBAGAI 
AGEN ANTI-HIPERTENSI DALAM TIKUS BERHIPERTENSI SPONTAN 
(SHR) 
ABSTRAK 
Hipertensi berkait dengan morbiditi dan mortaliti yang ketara. Penggunaan 
herba perubatan sebagai perubatan alternatif untuk menguruskan hipertensi meningkat 
secara exponen. Syzygium polyanthum (S. polyanthum), telah diakui sebagai agen 
antihipertensi secara tradisional. Kajian ini bertujuan untuk mengenalpasti kesan 
antihipertensi daripada ekstrak akueus daun S. polyanthum (AESP) dan mekanisme 
dengan menggunakan tikus berhipertensi spontan (SHR). Profil fitokimia, pelbagai ciri 
antioksidan dan aktiviti antihipertensi telah dinilai. Lima puluh ekor SHR jantan telah 
dibahagikan sama rata kepada 5 kumpulan: SHR tidak-terawat, Losartan-terawat, 3 
kumpulan dos AESP-terawat yang berbeza (1500 mg/kg, 1750 mg/kg dan 2250 
mg/kg) dan 10 WKY jantan sebagai kawalan. Semua rawatan diberi secara oral selama 
12 minggu. Tekanan darah sistolik (SBP) diukur setiap 2 minggu. Analisa biokimia, 
penanda tekanan oksidatif, dan tahap enzim Angiotensin-converting (ACE) telah 
dinilai pada penghujung kajian. Histologi aorta toraks dan ginjal telah dinilai 
menggunakan pewarnaan hematoksilin & eosin (H&E), dan mikroskop imbasan 
elektron (SEM). AESP mengandungi flavonoid dan fenol, dengan asid galik telah 
dikenalpasti. AESP menunjukkan aktiviti antioksidan dan perencat-ACE in vitro 
tinggi. Dalam SHR AESP-terawat; SBP menurun secara ketara, fungsi ginjal dan 
penanda tekanan oksidatif ditambahbaik. Walau bagaimanapun, hanya AESP (2250 
mg/kg) menurunkan kepekatan ACE secara ketara. Terdapat juga penambahbaikan 
histologi aorta toraks dan ginjal dalam SHR AESP-terawat. Oleh itu, kajian 
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mencadangkan pelbagai ciri antihipertensi AESP disebabkan oleh antioksidannya 
(terutamanya asid galik) dan aktiviti perencat ACE. Kajian juga mencadangkan 
mekanisma antihipertensi S. polyanthum melakukan aktiviti perencatan melalui 




EVALUATION OF AQUEOUS EXTRACT OF Syzygium polyanthum LEAVES 




Hypertension is associated with significant morbidity and mortality. The use 
of medicinal herbs as alternative medicines to manage hypertension is increasing 
exponentially. Syzygium polyanthum, has been claimed traditionally as an 
antihypertensive agent. This study aimed to determine the antihypertensive effects of 
the aqueous extract of S. polyanthum (AESP) leaves and its mechanisms using 
spontaneously hypertensive rats (SHR). The phytochemical profiling, antioxidant 
properties and antihypertensive activity were evaluated. Fifty male SHR were divided 
equally into 5 groups; untreated-SHR, Losartan-treated, 3 groups of AESP-treated 
with different dosages (1500 mg/kg, 1750 mg/kg and 2250 mg/kg), and 10 male WKY 
rats as control. All treatments were given orally for 12th weeks. Systolic blood pressure 
(SBP) was measured biweekly. Whereas, the biochemical analysis, oxidative stress 
markers and angiotensin-converting enzyme (ACE) level were evaluated at the end of 
the study. The histology of thoracic aorta and kidney were assessed using 
haematoxylin & eosin (H&E) staining, and scanning electron microscope (SEM). 
AESP contains flavonoids and phenols with gallic acid detected. AESP showed high 
in vitro antioxidant and ACE-inhibitory activities. In AESP-treated SHR; SBP reduced 
significantly, improved renal function and oxidative stress markers. However, only 
AESP (2250 mg/kg) significantly reduced ACE concentration. There was also 
histology improvement of the thoracic aorta and renal in AESP-treated SHR. Hence, 
the study suggests that antihypertensive properties of AESP are due to its antioxidant 
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(mainly gallic acid) and ACE inhibitory activity. Thus, this study reveals the 
antihypertensive mechanism of AESP exerted inhibitory activity through suppression 








1.1 Background of the study 
 
Natural products have been widely used as the primary materials and have played a 
crucial role in the development of a new drug as a lead compound. The use of 
medicinal herbs as alternative medicines to manage hypertension is increasing 
exponentially. The exponential is due to the conservative claim that these products are 
safe and free from side effects as used in ancient traditional Chinese, Greek-Unani and 
Ayurvedic medicines (Pandey et al., 2013).  
 
According to the World Health Organization (WHO, 2013a), around 80% of the total 
world population still relies on herbal products as primary health care. National Health 
and Morbidity Survey (NHMS) 2015 reported that 0.3% of hypertensive patients chose 
traditional and complementary medicine (T&CM) as their primary method of 
treatment (Institute for Public Health, 2015a). Another NHMS 2015 report (Volume 
IV) on T&CM showed that 40.4% of Malaysian respondents had chosen T&CM as 
their primary treatment prior to seeking conventional treatment (Institute for Public 
Health, 2015b). Eighteen point three percent (18.3%) used T&CM practices solely as 
alternative treatment without seeking conventional treatment.  
  
Many antihypertensive drugs are used to control hypertension, ranging from diuretics, 
renin inhibitors, angiotensin-converting enzyme inhibitors (ACEIs), angiotensin 
receptor blockers, calcium channel blockers, α-adrenergic blockers, β-adrenergic 
blockers to vasodilators. Due to the undesirable side effect of several synthetic drugs 
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and higher cost of antihypertensive drugs (Kiriyama et al., 2016), more experiments 
have now been concentrated on herbs and medicinal plants as potential hypertensive 
medicines. The trend was due to reports that medicinal plants contain thousands of 
bioactive compounds with therapeutic applications (Pan et al., 2013); i.e. phenolics, 
flavonoids, diterpenoids, and anthocyanins were thought to contribute to 
cardiovascular and hypertensive pharmacological potential (Fraga et al., 2019). Hence, 
people are more aware nowadays in seeking natural-based product approaches to 
replace the role of synthetic products for their treatment of hypertension and other 
diseases. 
 
Malaysia, a tropical country in Southeast Asia, has a rich diversity of flora and fauna, 
mostly herbs and medicinal plants. Malay people especially like to eat raw herbs in 
their daily diet as a condiment (ulam). Malaysia has more than 120 traditional ulam 
species available, ranging from shrubs to large trees (Abdul Raji et al., 2017). 
Syzygium polyanthum (Wight) Walp or locally known as 'Serai kayu' is one of the 
favourite ulam that has been consumed for ages. The plant is commonly grown at home 
and can be found abundantly on the local market. In addition to eating as ulam, the 
plant's leaves are usually added to "nasi kerabu" and "Kelantanese laksam" among 
Malay people. Besides, the plant has traditionally been used to treat various diseases 
such as hypertension, diabetes mellitus, diarrhoea, gastritis, skin diseases and 
hypercholesterolemia (Sumono and Wulan, 2008). The plant also has multi-biological 
properties such as antioxidant (Kusuma et al., 2011), antihypertensive (Ismail et al., 
2018), antihyperglycaemic (Widyawati et al., 2015a), and antimicrobial properties 




Although it is reported that the plant is useful for treating hypertension and other 
diseases, there is still limited scientific evidence of its antihypertensive activity. 
Therefore, it is worth scientifically determining the potential benefits of oral 
administration of this plant in the management of hypertension and its complications. 
Consideration is needed because the plant's young shoot has been claimed as a 
supplement to lower the blood pressure (decoction) among hypertensive people for 
many years. 
 
Later studies by Dafriani (2016) and Aris (2019) confirmed that the water decoction 
from S. polyanthum leaves in hypertensive patients, were able to reduce the blood 
pressure. In addition, recent animal studies (in vivo) have also been successful in 
demonstrating a further reduction in systolic blood pressure (SBP) over a short-term 
period of six weeks (Ahmad et al., 2017; Ismail et al., 2018). Even though both studies 
have confirmed S. polyanthum leaves have been able to lower blood pressure (Ahmad 
et al., 2017; Ismail et al., 2018), the mechanism for the lowering blood pressure is still 
not clear to date, and none of the long-term studies to confirm this finding have been 
conducted. This long-term study period (12 weeks of oral administration-in vivo) was 
therefore conducted to reconfirm the anti-hypertensive effect contributed by S. 
polyanthum leaves extract from low to high doses (1500 mg/kg, 1750 mg/kg and 2250 
mg/kg) as well as its possible anti-hypertensive grounds for determination. 
 
The reduction of blood pressure could be due to the high presence of antioxidant 
compounds (particularly gallic acid), a group of phenolic compounds in the leaves 
(Ismail et al., 2018). There is considerable evidence supporting the view that dietary 
intake of antioxidants and polyphenols may have an effect in preventing or reducing 
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hypertension (Baradaran et al., 2014), which further support the leaves are capable of 
lowering blood pressure. Some studies have also argued that the presence of 
angiotensin-converting enzyme inhibitor (ACEI) in the plant (Muthia et al., 2017; 
Ismail and Ahmad, 2019) may also be one of the potential reasons for reducing blood 
pressure. Yet less is known about S. polyanthum leaves' effect on the Renin 
Angiotensin Aldosterone System (RAAS) and blood pressure pathways. In order to 
confirm the possible bioactive compounds and the exact pathway responsible for this 
antihypertensive activity, an extensive study must be carried out. 
 
Because hypertension is associated with damage to target organs (especially blood 
vessels and kidneys) (Rahimmanesh et al., 2012; Renna et al., 2013), biochemical 
study, histological studies and oxidative stress activity were also essential to assess in 
hypertensive research (Siti et al., 2015; Allison, 2016; Ramli et al., 2017, Ramli et al., 
2018). In this current study, these three parameters would be done to assess the 




1.2 Problem statement 
 
Hypertension is one of the major public health problems due to its rapid increase and 
high prevalence worldwide. The disease can lead to numerous complications, such as 
heart disease, stroke and kidney failure, which increase the risk of death if not treated 
early. Although various antihypertensive drugs have been used to control 
hypertension, there is still insufficient absolute control of hypertension in Malaysia to 
date. In addition, these medications have been known to cause some detrimental side 
effects such as depression, delirium, sexual dysfunction, insomnia, and foetal 
anomalies, which influence people seeking natural plant-based antihypertensive agents 
(herbs); which are believed to have a wealth of antioxidants to combat cardiovascular 
risk and its complications. More scientific research is therefore needed to verify the 
efficacy and to clarify the safety profile of these herbal medicinal products for their 
antihypertensive potential.  
 
1.3 Objectives of the study 
 
1.3.1 General objective 
 
To evaluate the therapeutic effects of aqueous extract of S. polyanthum (AESP) leaves 






1.3.2 Specific objectives 
 
1. To determine the phytochemical compounds present in AESP. 
2. To determine the in vitro antioxidant properties and angiotensin-converting 
enzyme (ACE) activity in AESP 
3. To determine the effects of daily oral administration of AESP for 12 weeks 
on blood pressure in hypertensive rats.  
4. To determine the effects of daily oral administration of AESP for 12 weeks on 
biochemical parameters (renal function test, full blood count) and angiotensin-
converting enzyme level in hypertensive rats after 12 weeks. 
5. To determine the effects of daily oral administration of AESP for 12 weeks on 
histopathology of kidney and descending thoracic aorta in hypertensive rats 
after 12 weeks. 
6. To determine the effects of daily oral administration of AESP for 12 weeks on 
oxidative stress markers serum levels in hypertensive rats after 12 weeks. 
 
1.4 Significance of the study 
 
The present study provides a fundamental basis for further exploring the possible 
mechanism of action of the compound (especially gallic acid) found in S. polyanthum 
leaves as an antihypertensive agent with additional benefits for the improvement of the 
damaged target organ (kidney and blood vessel). This distinctive initiative should 
promote the use of an agricultural product of S. polyanthum as an innovative, practical 
food product that will help the health of the global community as more citizens become 
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more aware of their wellness. It will also reduce the country's dependence on imported 
vegetation and fruit while helping to improve the socio-economic status of local 
farmers in our country. In addition, citizens will also benefit from various health 
benefit from a number of pharma-nutritional medicinal products obtained from S. 
polyanthum, and part thereof. This diversification will enhance people's quality of life 
in line with the Malaysia's New Economic Model national government agenda; deliver 























2.1 Non-communicable disease (NCD) 
 
Non-communicable disease (NCD), also known as chronic diseases, can be life-
threatening and lead to mortality if adequate treatment is not provided. NCD is non-
infectious and cannot be transmitted between individuals, and is the result of a 
combination of genetic, environmental, physiological, and behavioural factors (WHO, 
2018).  
 
The four main categories of NCDs are cardiovascular disease (CVD), cancer, chronic 
respiratory diseases, and diabetes. According to the World Health Organisation (2018), 
NCD is reported to have killed approximately 41 million people worldwide per year, 
equivalent to 71% of total deaths, with the largest contributor being CVD. Deaths due 
to CVD are estimated at 17.9 million people each year, and more than half were due 
to hypertension, followed by cancers (9.0 million), respiratory diseases (3.9 million) 
and diabetes (1.6 million) (WHO, 2018). 
 
In Malaysia, NCD caused 73% of the total deaths in Malaysia (NHMS, 2015). The 
Second Burden of Disease Study for Malaysia, published by the Institute for Public 
Health (2012), ranked hypertension, high cholesterol, diabetes, high body mass index 
(BMI), and smoking among the major contributors to CVD and death. Hypertension 
is also known to be one of the metabolic risk factors associated with NCD that caused 






2.2.1 Definition   
  
Hypertension, also known as elevated blood pressure (BP), is commonly associated 
with increased cardiovascular disease. It is often referred to as a 'silent killer' because 
the symptoms are not too noticeable (Sheih et al., 2009). This is because hypertension 
can develop into more severe complications that are insidiously undetected. Based on 
the WHO report (2013b), the risk of death often increases when these complications 
are left untreated. 
 
Hypertension can be classified as primary hypertension and secondary hypertension. 
Primary hypertension can be defined as high BP with no known underlying condition. 
It accounts for 95% of all cases of hypertension. Primary hypertension is a 
heterogeneous disorder in which different patients have different causal factors leading 
to high BP (Carretero and Oparil, 2000). Secondary hypertension, on the other hand, 
can be defined as high BP with known aetiology, including renal parenchymal 
hypertension, primary aldosteronism, renovascular hypertension, and sleep apnea 
syndrome. Secondary hypertension was reported to account for 10% of hypertensive 
patients (Puar et al., 2016). 
 
2.2.2 Blood pressure categories  
 
Normal individuals have systolic blood pressure (SBP) of less than 120 mmHg and  
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a diastolic blood pressure (DBP) of less than 80 mmHg, i.e. 120/80 mmHg (Unger et 
al., 2020) (Table 2.1). A further increase of SBP between 120 and 129 mmHg is 
classified under "Elevated Blood Pressure." Whereas SBP falls between 130 and 139 
mmHg, and DBP falls between 80 and 89 mmHg, it is considered to be "Hypertension 
Stage I." In "Hypertension Stage II" the SBP is more than 140 mmHg, and the DBP is 
higher than 90 mmHg. If blood pressure continues to rise above 180 mmHg for SBP 
and above 120 mmHg for DBP, the situation is referred to as "Hypertensive Crisis;" 
where emergency treatment is needed.  
 
 
Table 2.1: Blood Pressure Categories. (Unger et al., 2020). 






Normal Less Than 120 and Less Than 80 
Elevated 120-129 and Less Than 80 
High Blood Pressure 
(Hypertension) Stage 1 
130-139 or 80-89 
High Blood Pressure 
(Hypertension) Stage 2 
140 or Higher or 90 or Higher 
Hypertensive Crisis 
(consult your doctor 
immediately) 

















2.2.3 Prevalence   
 
2.2.3(a) Worldwide  
 
Every year, the incidence of people with hypertension is rising rapidly worldwide. 
Currently, 1.13 billion people worldwide are living with hypertension (WHO, 2019). 
The overall prevalence was estimated at around 30% (NHMS, 2019). In the year 2015, 
one in four men and one in five women had hypertension, and it is expected that the 
number of people with hypertension will continue to rise to 1.56 billion by 2025 
(Tabrizi et al., 2016). Of the most worrying, hypertension is also reported to cause a 
total of 7.5 million deaths per year (WHO, 2019). Annual mortality is predicted at 23.5 
million people by 2030 (WHO, 2013).  
 
2.2.3(b) Malaysia  
 
The 2015 National Health and Morbidity Survey (NHMS) reported about 6.1 million 
people or about one in three adults with hypertension in Malaysia. Based on the 
available reports, the prevalence of hypertension differs between countries, countries 
and subgroups of a country's populations (Picon et al., 2012). The prevalence was 
higher in our neighbouring countries, Thailand (23.6%) and Singapore (16%). Based 
on NHMS 2015, 30.8% of males and 29.7% of females were affected by hypertension. 
There was also a generally increasing prevalence trend by age, from 6.7% in the 18-
19 age group to a peak of 75.4% in the 70-74 age group. The prevalence started to 
plateau from 2011 (32.6%) to 2015 (30.3%) (NHMS, 2019). For the main ethnic 
groups, Sabah & Sarawak Bumiputera has the highest prevalence at 36.4%, followed 
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by Malays at 34.0%, Chinese at 32.3% and Indians at 30.6% (IPH, 2011). Among 
these, Kelantan, along with Kedah, ranked the highest prevalence at 23.2% of 
undiagnosed hypertension.  The prevalence remained high, as there is still no 
significant improvement made by the community despite policies and task forces 
implemented by the government of Malaysia (IPH, 2011; MOH, 2014). 
 
2.2.4 Pathophysiological factors of hypertension development 
 
Numerous pathophysiological factors have been involved in the development of 
hypertension. Factors include neurohormonal factors, dietary factors, vascular factors, 
cellular mechanisms, oxidative stress, and other factors (Schulz et al., 2011; Acelajado 
et al., 2012). Numerous evidence has shown that oxidative stress is the predominant 
factor that leads to an increase in blood pressure (Ceriello, 2008; Rodrigo et al., 2011; 
Tsiropoulou et al., 2016). Details of pathophysiological factors that may contribute to 













Table 2.2:  Pathophysiological factors contribute to hypertension. (Schulz et al., 
2011; Acelajado et al., 2012). 
Pathophysiologic Factor 





Production of sodium retaining hormones 
Production and expression of vasoconstrictors 
Production and expression of vasodilators 























Cellular ion transport 
Adrenergic receptor activity 
 
Increased or decreased 















2.3 Oxidative stress in hypertension 
 
Oxidative stress is generally known to cause many types of disease. One of these is 
the key factors that make progress towards hypertension (Rodrigo et al., 2011; 
Montezano and Touyz, 2012) (Figure 2.1). This occurs when an imbalance exists 
between the production of reactive oxygen species (ROS) and the antioxidant defence 
system. In normal physiological conditions, ROS plays an important role in the 
maintenance of vascular function and its structure. However, under pathophysiological 
conditions (due to radical exposure, ageing, etc.), ROS overproduction will promote 
endothelial dysfunction, vascular remodeling and inflammation, ultimately leading to 
vascular damage and other complications, including kidney damage (Ozbek, 2012; 
Dikalov and Nazarewicz, 2013; Tsiropoulou et al., 2016). 
 
There are several types of ROS that can be detected within the vessel, including 
superoxide anion radical (O2˙
−), hydroxyl radical (·OH), singlet oxygen, hypochlorite 
radicals, nitric oxide radicals and various lipid peroxides (Landmesser and Harrison 
2001; Chandra et al., 2012). Due to the high amount of ROS and the simultaneous 
reduction of the antioxidant defence system, ROS will alter their molecules to become 
more toxic radicals. This toxic radical will promote various negative effects on cellular 
functions such as protein and lipid synthesis disruption, alteration of transcription 
factors which, in turn, influence various complications, including vascular function 
(Touyz et al., 2003; Touyz and Schiffrin, 2004) and kidney function and structure 







Figure 2.1: Oxidative stress is a key factor that leads to hypertension (Santilla et 
al., 2015). Overproduction of ROS promotes the reduction of NO and at the same 
time generates high ANG II level. This condition had caused endothelial 
dysfunction, which lastly promoting hypertension. NO: nitric oxide, ROS: 















Thus, in order to prevent uncontrolled ROS from rising, the redox equilibrium system 
becomes an important key to maintaining the correct functionality of cellular functions 
(Schieber and Chandel, 2014; Kurutas, 2016). Redox systems include enzymatic 
antioxidants (naturally produced by our body, such as catalase (CAT), glutathione 
peroxidase (GPx) and superoxide dismutase (SOD) and non-enzymatic antioxidants 
(externally supplied from other sources, such as vitamins A, C and E, glutathione and 
several antioxidants present in food). Relatively, enzymatic antioxidants have been 
considered to be the best known antioxidant defence system for ROS 
normalisation compared to non-enzymatic antioxidants (Li et al., 2016; Aziz et al., 
2019) and have thus far been used as oxidative stress biomarkers in many studies (Sáez 
et al., 2004; Ahmad et al., 2013). 
 
Various methods have been developed to measure and evaluate oxidative stress in 
hypertension, including markers for lipid peroxidation, protein oxidation and 
antioxidant status (Tsiropoulou et al., 2016). The most commonly used assays are lipid 
peroxidation (such as malondialdehydes (MDA) assay) and antioxidant status (such as 
total antioxidant capacity (TAC) assay, SOD assay, CAT assay and GPx assay). On 
the basis of literature, these assays are important to measure in order to determine the 
biological redox status, at the same time to assess the hypertensive state and 
progression and the health-enhancing effects of the antioxidant supply in hypertensive 
people (Marrocco et al., 2017). This is because many studies have shown that 
hypertensive people usually have higher levels of MDA (Ahmad et al., 2013; 
Ekeanyanwu et al., 2016) as well as lower levels of SOD activity (Sáez et al., 2004; 
Ahmad et al., 2013; Baradaran et al., 2014), CAT levels (Sáez et al., 2004; Ahmad et 
al., 2013) and TAC levels (Onuoha et al., 2013).  
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2.4 Complications and consequences of hypertension  
 
Hypertension due to oxidative stress is well documented to cause damage to the end 
organ (Simão et al., 2011). Several important organs, such as the heart, brain, kidneys, 
blood vessels, and eyes, are the major target organs that are commonly affected during 
uncontrolled hypertension (Schmeider, 2010; WHO, 2019). Growing evidence has 
shown that damage to blood vessels and kidneys have had a major impact 
(Rahimmanesh et al., 2012; Lyle and Taylor., 2019). The total damage to the 
hypertensive-induced end organ is summarised in Table 2.3. 
 
Table 2.3: End organ damage in arterial hypertension. (Schmeider, 2010).  
End organ damage in hypertension 
Vasculopathy 
• Endothelial dysfunction 
• Remodeling 
• Generalized atherosclerosis 
• Arteriosclerotic stenosis 
• Aortic aneurysm 
Cerebrovascular damage 
• Acute hypertensive encephalopathy 
• Stroke 
• Intracerebral haemorrhage 
• Lacunar infarction 




• Left ventricular hypertrophy 
• Atrial fibrillation 
• Coronary microangiopathy 
• CHD, myocardial infarction 





• Chronic renal insufficiency 









2.4.1 Blood vessel 
 
2.4.1(a) Normal structure of blood vessel 
 
The blood vessel consists of three layers; tunica intima, media and external (Zhao et 
al., 2015) (Figure 2.2). Tunica intima, the innermost layer, is composed of a single 
layer of endothelial. The lining is separated from the tunica medium by an internal 
elastic lamina. Whereas, the middle layer; the tunica media mainly consists of a large 
number of smooth muscle cells, a large number of elastic fibres and connective tissues. 
The layer of the media is distinguished from the external layer by the external elastic 
lamina. Apart from that, the outer layer; the outer tunica consists of various elements, 
including connective tissues, vasa vasorum, fibroblasts and collagen fibres, which help 
to retain the structure of the vessel. The layer is also composed of nerve ends and 
perivascular adipose tissue. 
 
In normal vessels, two important components of the blood vessels responsible for 
maintaining the tone of the vessel (vasoconstriction and vasorelaxation) are vascular 
smooth muscle cells and endothelial cells. The lumen diameter of the blood vessel is 
controlled by the smooth muscle cells in the tunica media. It regulates the tone of the 
vessel by expanding circularly around the lumen (Sandoo et al., 2010). In contrast, 
endothelial cells found on the surface of the endothelial layer regulate the tone of the 
blood vessel by releasing vasoconstrictors and vasodilators factors (Vanhoutte et al., 
2009; Rajendran et al., 2013) including nitric oxide, prostacyclin, angiotensin II (Ang 
II), endothelin-1, leukotrienes, and reactive oxygen species (ROS) when endothelial 







Figure 2.2: Blood vessel layers. The layers consist of tunica intima, tunica media, and 














Other than that, endothelial cells are also responsible for maintaining the homeostasis 
process (Durand and Gutterman, 2013; Wang et al., 2015), controlling the flow of 
blood, regulating the autocrine-paracrine mechanism (Sena et al., 2013), preventing 
thrombosis (Verhamme and Hoylaerts, 2006; Vanhoutte et al., 2009), regulating the 
balance between coagulation and fibrinolysis, reducing platelets-leucocytes adhesion 
(Verhamme and Hoylaerts, 2006; Vanhoutte et al., 2009), and producing inflammatory 
mediators to prevent inflammation activity (Calvin et al., 2014). Details of the function 



























2.4.1(b) Alteration of vascular components 
 
A small decrease in the lumen size of the blood vessel due to hypertensive oxidative 
stress significantly increases the resistance to blood flow. This prolonged blood 
resistance will alter the structure and function of the vessel (Lyle & Taylor, 2019). The 
alterations include vascular remodeling, endothelial dysfunction, increased vascular 
stiffness, and inflammation (Rodrigo et al., 2011; Touyz, 2012; Renna et al., 2013; 
Montezano et al., 2014). The most common hypertensive complications reported are 
vascular remodeling and endothelial dysfunction (Savoia et al., 2011; Rahimmanesh 
et al., 2012; Renna et al., 2013).  
 
Figure 2.4 shows the schematic representation of vascular remodeling in arteries in 
response to hypertension. Vascular remodeling is indicated by high proliferation and 
hypertrophy of the smooth muscle cell, migration of monocytes, reduction in elastin 
levels, high inflammatory cell count, increased apoptosis and increased fibrosis 
(collagen, fibronectin and extracellular matrix deposition), resulting in thickening of 
the vascular media and narrowing of the vascular lumen (Intengan and Schiffrin, 2001; 
Touyz and Schiffrin, 2004; Paneni et al., 2017).      
 
In addition, vascular remodeling can also be found on the endothelial surface of the 
blood vessel. In normal levels of shear stress (15 - 40 dynes/cm2), endothelial cells 
line the endothelial layer; normally elongate, align in the direction of blood flow and 
maintain the barrier function. Too much blood flow, however, will trigger abnormal 
shear stress. This pressure will cause high friction on the endothelial surface; the 





Figure 2.4: The blood vessel underwent vascular remodeling in response to increased 
resistance to blood flow. Cellular growth of vascular smooth muscle cells (VSMCs), 
cell migration, rearrangement of VSMCs, extracellular matrix (ECM) deposition, 












In addition, damage to the vessel can also be assessed by its functional alterations. In 
pathological conditions, the function of the endothelial cell will be compromised as it 
releases a high number of vasoconstrictor factors. This endothelial dysfunction will 
reduce vascular relaxation and increase vascular contractile activity (Paneni et al., 
2017). Many other characteristics of endothelial dysfunction include cell proliferation, 





2.4.2(a) Normal structure of the kidney 
 
The kidney plays a number of crucial functions. It filters approximately 120 to 150 
quarts of blood to produce 1 to 2 quarts of urine, consisting mainly of waste and extra 
fluid (NIDDK, 2014). A kidney can be divided into three main inner regions (Figure 
2.5); renal cortex (outer part of the kidney), renal medulla (inner part of the kidney) 
and renal pelvis (vessel and nerve of the kidney). There are millions of functional 
nephronic units or nephron that responsible for filtering the blood, removing waste 
materials and toxins such as urea, creatinine and uric acid in the form of urine. The 
nephron itself consists mainly of the renal corpuscle and the renal tubule. There are 
two main components in the renal corpuscle; the glomerulus and its surrounding 
Bowman capsule.  
 
The glomerulus is characterised as having a tight capillary ball that supported by a 
cytoplasmic bundle of actin-like filaments; mesangial cells. These mesangial 
